BETA
Your AI-Trained Oncology Knowledge Connection!
FDA Approves Perioperative Pembrolizumab Plus Radiation in HNSCC
Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.
TPS 38 ELCIN: Elacestrant in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer: An Open-Label, Multicenter, Phase 2 Study
Revumenib Plus Azacitidine/Venetoclax Appears Safe in Older NPM1/KMT2Ar AML
The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.
Sasanlimab Combo Improves EFS “Across the Board” in BCG-Naïve NMIBC
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Geriatric Assessment Finds Older and Younger Adults With PTCL Had Similar Outcomes
Tetiana Skrypets, MD, highlighted that older adults with PTCL may be treated as younger adults if they pass the geriatric assessment.
FDA Approves Mitomycin Solution in Low-Grade Intermediate-Risk NMIBC
Data from the phase 3 ENVISION trial support the FDA approval of the mitomycin solution for patients with recurrent, low-grade, intermediate-risk NMIBC.
FDA Grants Fast Track Designation to RAD101 Imaging for Brain Metastases
The developer plans to share topline results for RAD101 in various solid tumors from the supporting phase 2b trial in the second half of 2025.
Adverse Sexual Health Outcomes Appear More Likely in Women With CRC
In patients 39 years or younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.
Encorafenib Combo May Limit Recurrence Risk in BRAF V600+ Melanoma
Phase 3 data demonstrate the potential utility of BRAF/MEK inhibition in the adjuvant setting for patients with stage IIB/IIC BRAF V600–mutant melanoma.
FDA Approves Zanubrutinib Tablets in Multiple Hematologic Indications
Zanubrutinib tablets were found to have the same efficacy and safety as capsules based on 2 single-dose, open-label randomized phase 1 studies.
Tivozanib Shows Efficacy in Pretreated Metastatic RCC
There appeared to be no extra benefit with the addition of nivolumab to tivozanib among patients included in the phase 3 TiNivo-2 trial.
Iopofosine I 131 Shows Preliminary Survival Benefit in Pediatric R/R Glioma
The safety profile of iopofosine I 131 in the phase 1b CLOVER-2 trial appears consistent with prior reports of the agent.
Elacestrant Regimens Show Activity in Pretreated ER+/HER2– Breast Cancer
Data from the ELEVATE trial may support elacestrant as an endocrine therapy backbone in ER-positive, HER2-negative metastatic breast cancer.
FDA Approves Taletrectinib in ROS1+ NSCLC
Supporting results for the approval of taletrectinib in ROS1+ NSCLC come from the TRUST-I and TRUST-II trials.
Preoperative Counseling Increases Shared Decision-Making in CRC Surgery
Counseling received prior to colorectal surgery using 3-dimensional–printed anatomic models reduced mean anxiety scores vs conventional counseling.
Robust Responses Occur With UGN-102 in Recurrent Intermediate-Risk NMIBC
Data from the ENVISION trial may support UGN-102 as a well-tolerated, efficacious treatment in non–muscle-invasive bladder cancer.
microRNA-based Signatures Predict irAEs in Patients Receiving Anti-PD1 Treatment
Data from a study shared at the 2025 ASCO Annual Meeting showed that a microRNA-based model was able to predict irAEs in various cancers for those on anti-PD1 therapy.
Frontline Nivolumab Combo Shows Enduring Activity in MSI-H Gastric Cancer
Phase 2 data may support nivolumab plus low-dose ipilimumab as a promising option in patients with microsatellite instability–high gastric cancer.
microRNA-Based Model Predicts SBRT Outcomes in Soft Tissue Sarcomas
Identifying which patients are at risk of distant failure may assist oncologists in deciding who should receive neoadjuvant radiation, according to Joanne B. Weidhaas, MD, PhD, MBM.
China’s CDE Accepts Marketing Application for Pimicotinib in TGCT
In the phase 3 MANEUVER trial, pimicotinib improved the objective response rate vs placebo in patients with tenosynovial giant cell tumor.
Lurbinectedin Maintenance Combo Earns FDA Priority Review in ES-SCLC
The FDA has set a Prescription Drug User Fee Act date of October 7, 2025, for its decision on approving the lurbinectedin combination in this SCLC population.
Epcoritamab Elicited Sustained PFS and OS at 3 Years in R/R LBCL
Epcoritamab monotherapy led to long-term disease-free remissions in patients with relapsed/refractory large B-cell lymphoma who achieved complete response at 2 years.
New microRNA Models Predict Responses and Toxicities in Various Cancers
Joanne B. Weidhaas, MD, PhD, MBM, presented 2 abstracts based on microRNA technology at the 2025 ASCO Annual Meeting that demonstrated predictive power.
FDA Lifts Hold on IFx-2.0 in Advanced/Metastatic Merkel Cell Carcinoma
A phase 3 trial evaluating frontline IFx-2.0 with pembrolizumab in advanced/metastatic Merkel cell carcinoma is planned to start later in June 2025.
Satri-Cel Improves Survival vs Physician’s Choice in Pretreated Gastric/GEJ Cancer
Satri-cel led to a median PFS of 3.25 months vs 1.77 months with physician’s choice in patients with pretreated gastric or gastroesophageal cancer.
Cilta-Cel Demonstrates "Curative Potential" in R/R Multiple Myeloma
The median overall survival with cilta-cel exceeds 5 years among patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 trial.
Sacituzumab Tirumotecan Enhances Efficacy in Pretreated EGFR-Mutant NSCLC
Sacituzumab tirumotecan showed a manageable safety profile compared to docetaxel in patients with EGFR-mutant advanced non–small cell lung cancer.
Fostering a Team-Based Approach to Elevate Neuro-Oncology Care
Specialties including neurosurgery, radiation oncology, and neurorehabilitation all play a notable role in the care of patients with brain tumors.
CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025
An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.
Maximizing Quality of Life From the Get-Go in Neuro-Oncology Care
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
